Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,800 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.00, for a total transaction of $27,000.00. Following the transaction, the chief executive officer now owns 338,575 shares in the company, […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,800 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.00, for a total transaction of $27,000.00. Following the transaction, the chief executive officer now owns 338,575 shares in the company, […]
BOSTON, May 16, 2024 Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage.
Entrada Therapeutics, Inc : Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.